PBYI
$6.14
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Intraday
Recent News
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology Q4 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported fourth-quarter 2025 total revenue of $75.5 million, driven by NERLYNX product revenue and a sharp increase in royalty revenue, according to management’s comments on the company’s earnings call held February 26, 2026. Product revenue net, which management sa
Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Puma Biotechnology Inc (PBYI) reports robust revenue growth and outlines promising clinical trial advancements despite challenges in prescription trends.
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +20.83% and +11.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?